However, we also observed significant HCC risk reduction with antiviral therapy in patients without cirrhosis who were older than 40 years with modestly elevated HBV DNA > 2000 IU/mL even if ALT < 2 × ULN, the population who currently may not meet criteria for treatment by some guidelines. This evidence concerns the gene GPT and hepatocellular carcinoma.